Skincare device maker La Lumiere has raised $20m in a series B round featuring Johnson & Johnson that will fund the commercialisation of its IlluMask product.
US-based skincare company La Lumiere received $20m in series B funding on Tuesday from Johnson & Johnsoon Development Corporation, the corporate venturing unit of healthcare company Johnson & Johnson, and venture capital firm Swan & Legend Venture Partners.
La Lumiere develops light-based phototherapy devices. The company’s debut product is the IlluMask, which offers treatments to the home market previously only available in dermatology offices.
The funding will support the commercialisation of IlluMask across the US, as well as the research and…
